Centessa Pharmaceuticals plc (NASDAQ: CNTA) has announced the commencement of an underwritten public offering of American Depositary Shares (ADSs), each representing one ordinary share. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs offered in the public offering. The proposed offering is subject to market and other conditions.
Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are acting as joint book-running managers for the offering, while Oppenheimer & Co., Truist Securities, and LifeSci Capital are acting as co-lead managers.
The ADSs are being offered pursuant to a registration statement on Form S-3 that was filed with the Securities and Exchange Commission (SEC) on September 11, 2024, and became automatically effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website.
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company focused on discovering, developing, and delivering transformational medicines for patients. The company is pioneering a new class of potential therapies within its Orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue, and other symptoms across neurological, neurodegenerative, and neuropsychiatric disorders.
No specific financial metrics or changes from the previous period were provided in the press release. The market has reacted to these announcements by moving the company's shares 18.46% to a price of $26.70. Check out the company's full 8-K submission here.
